Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1804 results
November 2018
-
Women in Science: Cyndy Grosskreutz
Physician-scientist Cyndy Grosskreutz explains why she transitioned from academia to industry.
-
Women in Science: Alexandra Bach-Weidmuller
Alexandra Bach-Weidmuller, Head of Program and Project Management at NIBR, describes her path to leadership as lateral instead of upward.
-
Media ReleaseNovartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021…
-
Media ReleaseSandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needsDecision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
-
Media ReleaseNovartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncologyAdditional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…
-
The realities of living with premenopausal metastatic breast cancer
Receiving a breast cancer diagnosis is difficult, but these young women faced an especially challenging diagnosis: stage IV metastatic breast cancer.
-
The importance of caregivers
Melanoma survivor T.J. Sharpe discusses his personal experience with cancer and the important role caregivers play in a patient’s road to recovery.
October 2018
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz)Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing…
-
Media ReleaseNovartis announces clinical collaboration with Pfizer to advance the treatment of NASHAgreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMDYear two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…
-
Flexibility at Novartis: Robert Gschwentner and Stefan Lackner
Gschwentner and Lackner discuss the advantages of their job share.
-
Flexibility at Novartis: Ana Graf
Graf explains how flexible working has contributed to her success.
Pagination
- ‹ Previous page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- …
- 151
- › Next page